Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Drummond R, Baru A, Dutkiewicz M, et al. Physicians’ real-world experience with IDegLira: results of a European survey. BMJ Open Diabetes Research and Care 2018;6:e000531. doi: 10.1136/bmjdrc-2018-000531
The authors traced some formatting errors in figures 2 and 3. The correct versions are now available below:
Figure 2 Satisfaction of respondents with IDegLira compared with basal-bolus. HbA1c, glycated hemoglobin; IDegLira, insulin degludec/liraglutide.
Figure 3 Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose levels; and (B) concerns with IDegLira compared with basal-bolus therapy. GI, gastrointestinal; IDegLira, insulin degludec/liraglutide.